VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 358 EUR | +1.13% |
|
-0.56% | -0.42% |
| May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play |  |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
| Sales 2024 * | 1.38B 1.49B | Sales 2025 * | 1.48B 1.6B | Capitalization | 3B 3.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 139M 151M | Net income 2025 * | 155M 168M | EV / Sales 2024 * | 2.23 x |
| Net Debt 2024 * | 74.94M 81.27M | Net cash position 2025 * | 43.1M 46.74M | EV / Sales 2025 * | 2 x |
| P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
19.5
x | Employees | 5,459 |
| Yield 2024 * |
0.41% | Yield 2025 * |
0.45% | Free-Float | 48.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 day | +1.13% | ||
| 1 week | -0.56% | ||
| 1 month | +3.17% | ||
| 3 months | +7.83% | ||
| 6 months | +24.96% | ||
| Current year | -0.42% |
1 week
350.00
361.00
1 month
343.00369.50
Current year
316.50377.50
1 year
232.50377.50
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philippe Capron
BRD | Director/Board Member | 65 | 03-12-31 |
| Chairman | 59 | 97-12-31 | |
| Director/Board Member | 63 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 358 | +1.13% | 6,717 |
| 24-05-30 | 354 | +0.85% | 2,676 |
| 24-05-29 | 351 | -0.28% | 2,212 |
| 24-05-28 | 352 | -2.22% | 2,673 |
| 24-05-27 | 360 | -.--% | 843 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
358
EUR
Average target price
373.3
EUR
Spread / Average Target
+4.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.42% | 3.25B | |
| -14.09% | 77.37B | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| +18.07% | 1.73B | |
| -16.99% | 1.38B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B | |
| -6.77% | 976M | |
| -2.89% | 892M |
- Stock Market
- Equities
- VIRP Stock
